Tobin Chettiath, PharmD, MBA is currently Senior Medical Director, Metabolic, North America at Ultragenyx Pharmaceutical and has been with the company since 2017. He has also served as Director of Medical Science Liaisons, Metabolic, North America at Ultragenyx. Prior to joining Ultragenyx, Tobin has spent the last 14 years working on rare diseases in the plasma pharmaceutical industry, including with companies such as Bayer Biologicals (later Talecris and now part of Grifols), Octapharma, and Baxter Bioscience (later Baxalta, Shire and now Takeda). Tobin received a bachelor degree in Biochemistry and Cell Biology from the University of California, San Diego, a Doctor of Pharmacy degree from the University of Illinois in Chicago, and a Master in Business Administration degree from The George Washington University.
